CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells

Cisplatin-pemetrexed is a frequently adopted first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) ineligible for biological therapy, notwithstanding its limited efficacy. In the present study, the RAL cell line, an epidermal growth factor receptor (EGFR)-wild-type, p53-...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Int J Oncol
Huvudupphovsmän: Zamagni, Alice, Pasini, Alice, Pirini, Francesca, Ravaioli, Sara, Giordano, Emanuele, Tesei, Anna, Calistri, Daniele, Ulivi, Paola, Fabbri, Francesco, Foca, Flavia, Delmonte, Angelo, Molinari, Chiara
Materialtyp: Artigo
Språk:Inglês
Publicerad: D.A. Spandidos 2020
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170038/
https://ncbi.nlm.nih.gov/pubmed/32236605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijo.2020.5024
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk